Change search
ReferencesLink to record
Permanent link

Direct link
Cancer classification using the Immunoscore: a worldwide task force
Show others and affiliations
2012 (English)In: Journal of Translational Medicine, ISSN 1479-5876, Vol. 10, 205- p.Article, review/survey (Refereed) Published
Abstract [en]

Prediction of clinical outcome in cancer is usually achieved by histopathological evaluation of tissue samples obtained during surgical resection of the primary tumor. Traditional tumor staging (AJCC/UICC-TNM classification) summarizes data on tumor burden (T), presence of cancer cells in draining and regional lymph nodes (N) and evidence for metastases (M). However, it is now recognized that clinical outcome can significantly vary among patients within the same stage. The current classification provides limited prognostic information, and does not predict response to therapy. Recent literature has alluded to the importance of the host immune system in controlling tumor progression. Thus, evidence supports the notion to include immunological biomarkers, implemented as a tool for the prediction of prognosis and response to therapy. Accumulating data, collected from large cohorts of human cancers, has demonstrated the impact of immune-classification, which has a prognostic value that may add to the significance of the AJCC/UICC TNM-classification. It is therefore imperative to begin to incorporate the ` Immunoscore' into traditional classification, thus providing an essential prognostic and potentially predictive tool. Introduction of this parameter as a biomarker to classify cancers, as part of routine diagnostic and prognostic assessment of tumors, will facilitate clinical decision-making including rational stratification of patient treatment. Equally, the inherent complexity of quantitative immunohistochemistry, in conjunction with protocol variation across laboratories, analysis of different immune cell types, inconsistent region selection criteria, and variable ways to quantify immune infiltration, all underline the urgent requirement to reach assay harmonization. In an effort to promote the Immunoscore in routine clinical settings, an international task force was initiated. This review represents a follow-up of the announcement of this initiative, and of the J Transl Med. editorial from January 2012. Immunophenotyping of tumors may provide crucial novel prognostic information. The results of this international validation may result in the implementation of the Immunoscore as a new component for the classification of cancer, designated TNM-I (TNM-Immune).

Place, publisher, year, edition, pages
2012. Vol. 10, 205- p.
National Category
Medical and Health Sciences
URN: urn:nbn:se:umu:diva-67413DOI: 10.1186/1479-5876-10-205ISI: 000315104900001OAI: diva2:615070
Available from: 2013-04-08 Created: 2013-03-18 Last updated: 2015-03-24Bibliographically approved

Open Access in DiVA

fulltext(1155 kB)246 downloads
File information
File name FULLTEXT02.pdfFile size 1155 kBChecksum SHA-512
Type fulltextMimetype application/pdf

Other links

Publisher's full text

Search in DiVA

By author/editor
Palmqvist, Richard
By organisation
In the same journal
Journal of Translational Medicine
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
Total: 246 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 54 hits
ReferencesLink to record
Permanent link

Direct link